Advertisement
Product › Details
OncoScreen service (microfluidic 3D culture screening platform)
Next higher product group | drug screening (service) | |
Status | 2018-07-06 sales start | |
Organisation | ScreenIn3D Ltd. | |
Group | AMSBIO (AMS Biotechnology) (Group) | |
AMS Biotechnology (Europe) Ltd.. (7/6/18). "Press Release: AMSBIO and University of Strathclyde Jointly Launch New Screening Company".
ScreenIn3D (Glasgow, UK) is a new joint venture company set up by AMSBIO and the University of Strathclyde exploiting the latest advances in microfluidics and 3D culture to develop a novel microfluidic screening platform.
The unique combination of microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids is designed to make drug discovery more closely relevant with what happens in the body. The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies do 100x more testing for the same money spent as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.
OncoScreen service - the first application platform launched by ScreenIn3D is targeted at improving anticancer drug treatment and accelerating development of new personalized medicine solutions using patient-derived tissue.
Chosen by the Society for Laboration Automation & Screening (SLAS Europe) as an exciting innovation technology company (presented at SLAS Europe 2018), the ONCOSCREEN service offers users the ability to reduce and replace animal models in cancer research. As well as offering 100-fold greater throughput than existing cancer screening assays for same cost – ONCOSCREEN also provides a larger screening capability of patient-derived tissue than any existing services.
Alex Sim, Managing Director of AMSBIO and ScreenIn3D said:
The OncoScreen platform presents exciting possibilities for testing patient-derived multicellular tumor spheroids/organoids (comprising cancer cells, stromal cells, cancer stem cells and/or immune cells) for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations”.
He added:
We are actively seeking partners and investors to fast track development of further platforms. Additional R&D grants to enhance our immunotherapy and neuroscience programs are being applied for with our collaborators."
Record changed: 2023-07-10 |
Advertisement
More documents for drug screening (service)
- [1] Novalix S.A.S.. (11/30/21). "Press Release: Novalix Signs Partnership Agreement to Design and Screen Sanofi’s New DNA-Encoded Libraries". Strasbourg....
- [2] Aragen Life Sciences Pvt. Ltd.. (6/29/21). "Press Release: Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim". Hyderabad....
- [3] Velabs Therapeutics GmbH. (1/7/20). "Press Release: Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics". Heidelberg & Jena....
- [4] Charles River Laboratories International, Inc.. (5/1/18). "Press Release: Charles River Laboratories Expands Services for Early Discovery Screening". Wilmington, DE....
- [5] Metrion Biosciences Ltd.. (2/12/18). "Press Release: Metrion Biosciences Establishes Scientific Advisory Board". Cambridge....
- [6] Enamine Ltd.. (1/10/18). "Press Release: Enamine Supplies DSI Poised Fragment and Analogue Libraries to Diamond Light Source XChem Facility and SGC Oxford Screening Efforts". Kiev & Oxford....
- [7] Genedata AG. (9/27/17). "Press Release: Genedata Screener Strengthens Collaborative Research at Axxam". Basel....
- [8] AbCellera Biologics, Inc.. (9/12/17). "Press Release: AbCellera Launches Antibody Discovery Collaboration with GSK". Vancouver, BC....
- [9] Eurofins Scientific. (7/31/17). "Press Release: Eurofins Expands Its Offering and Footprint in Drug Discovery Services with the Acquisition of DiscoverX"....
- [10] Merck KGaA. (4/20/17). "Press Release: Merck Partners with University of California, San Diego (UCSD) to Fight Neglected Tropical Diseases". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top